Ethic Inc. Acquires 720 Shares of Bruker Corporation $BRKR

Ethic Inc. lifted its position in shares of Bruker Corporation (NASDAQ:BRKR) by 7.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,882 shares of the medical research company’s stock after purchasing an additional 720 shares during the period. Ethic Inc.’s holdings in Bruker were worth $413,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of BRKR. Allworth Financial LP grew its stake in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Bruker by 1,354.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the last quarter. Parallel Advisors LLC grew its stake in Bruker by 63.0% in the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Bruker in the 1st quarter valued at about $42,000. Finally, Blue Trust Inc. grew its stake in Bruker by 63.1% in the 2nd quarter. Blue Trust Inc. now owns 1,385 shares of the medical research company’s stock valued at $57,000 after buying an additional 536 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares of the company’s stock, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 27.30% of the company’s stock.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $37.74 on Thursday. The firm has a market cap of $5.73 billion, a PE ratio of 72.58, a price-to-earnings-growth ratio of 5.45 and a beta of 1.20. The firm’s fifty day moving average is $34.32 and its 200-day moving average is $37.00. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.64.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million for the quarter, compared to analyst estimates of $811.17 million. During the same quarter last year, the firm posted $0.52 EPS. Bruker’s revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Sell-side analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, September 23rd. Bruker’s payout ratio is 38.46%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the stock a “hold” rating in a research report on Tuesday, August 5th. Barclays decreased their target price on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Citigroup decreased their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company decreased their target price on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Bruker has an average rating of “Hold” and a consensus target price of $51.00.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.